✦ LIBER ✦

A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma

✍ Scribed by Micheal R. Grever; Jacqueline Benedetti; Stanley P. Balcerzak; Sarah A. Taylor; Thomas P. Miller; Shaker R. Dakhil

Publisher: Springer US
Year: 1994
Tongue: English
Weight: 188 KB
Volume: 12
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873969

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of bleomycin. A Sout

Phase II evaluation of bleomycin. A Southwest Oncology Group study

✍ Charles D. Haas; Charles A. Coltman Jr.; Jeffrey A. Gottlieb; Arthur Haut; James 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 2 views

Bleomycin given intravenously (i.v.) or intramuscularly (i.m.) in twice-weekly doses of 10 mg/mz was evaluated for efficacy and toxicity in 382 patients. Responses were observed in 11/27 Hodgkin's diseases, 10/30 lymphomas, 9/22 squamous cell cancers of ectodermal origin, 12/26 germinal cancers, and

Phase II evaluation of mitoxantrone in a

Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

✍ Sarah A. Taylor; Thomas Fleming; Daniel D. Hoff; Joseph D. McCracken; Ronald M. 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 242 KB

Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin less than or equal to 1.5 mg% received mitoxantrone 12 mg/m2 i.v

Phase ii evaluation of ftorafur in previ

Phase ii evaluation of ftorafur in previously untreated colorectal cancer: A southwest oncology group study

✍ Thomas Buroker; Fernando Padilla; Carl Groppe; Gerald Guy; Joseph Quagliana; Jos 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 2 views

Phase II evaluation of galactitol in hea

Phase II evaluation of galactitol in head and neck cancer: A southwest oncology group study

✍ Haas, Charles D. ;Lehane, Daniel ;Bottomley, Richard 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB

## Abstract A phase II evaluation of DAG in head and neck cancer patients produced one partial response and one patient with prolonged stable disease from nine fully evaluable patients with squamous carcinomas. One partial response was produced in a patient with anaplastic thyroid carcinoma. No dru

Phase II evaluation of esorubicin (4′ de

Phase II evaluation of esorubicin (4′ deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study

✍ Clarence B. Vaughn; Sydney E. Salmon; Thomas R. Fleming 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 335 KB

Esorubicin (4' deoxydoxorubicin) is a new analogue of the anthracycline, doxorubicin. This compound lacks the hydroxyl group at 4' position on the amino sugar of the anthracycline. Phase II study was designed to determine the clinical response rate and to define the qualitative and quantitative toxi

A phase II evaluation of cisplatin in un

A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study

✍ Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balc 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 240 KB

Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disea